Back to CVE records
High 7.0Published Aug 30, 2026

CVE-2026-82649SiYuan before 3.8.1 Local Privilege Escalation via Uncontrolled Search Path

Updated under an hour ago ()

Does this affect you?

It affects siyuan-note siyuan. Add what you run to find out whether that includes you.

No exploitation reported and no EPSS estimate yet.

SiYuan Windows installer before version 3.8.1 (affected versions >= 2.0.14) contains an uncontrolled search path element vulnerability in its NSIS installer, which invokes system executables such as TASKKILL by name rather than by absolute path. Because NSIS nsExec::Exec resolves these calls using a search path that includes the installer's own launch directory ahead of System32, an attacker who plants a malicious executable (e.g., a renamed TASKKILL.exe) in that directory can have it executed when the installer runs. These calls occur in electron-builder's preInit hook before the license page is displayed, and with an all-users (elevated) install the planted binary executes with an elevated token, resulting in local privilege escalation.

CVSS
7.0 HIGH (v4.0, CNA)CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:P/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N
Weakness (CWE)
CWE-427
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
Not loaded for this CVE
Assigned by
VulnCheck
NVD analysis
Deferred
Record last updated
Sep 1, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

Affected products
siyuan-note siyuan
siyuan_note:siyuan (from the name)
from 2.0.14 before 3.8.1; 3.8.1 not affected
CNA record

References

  • vendor-advisory
  • patch
  • third-party-advisory

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.